Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Cash from Financing Activities (2018 - 2025)

OptimizeRx (OPRX) has disclosed Cash from Financing Activities for 12 consecutive years, with -$3.4 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 22.1% to -$3.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$8.8 million through Dec 2025, down 79.15% year-over-year, with the annual reading at -$8.8 million for FY2025, 79.15% down from the prior year.
  • Cash from Financing Activities hit -$3.4 million in Q4 2025 for OptimizeRx, down from -$258000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $70.2 million in Q1 2021 to a low of -$12.0 million in Q3 2022.
  • Historically, Cash from Financing Activities has averaged $3.5 million across 5 years, with a median of -$440000.0 in 2023.
  • Biggest five-year swings in Cash from Financing Activities: soared 62476.44% in 2021 and later crashed 3080.6% in 2023.
  • Year by year, Cash from Financing Activities stood at $1.1 million in 2021, then crashed by 802.65% to -$7.4 million in 2022, then soared by 586.46% to $36.2 million in 2023, then crashed by 107.8% to -$2.8 million in 2024, then fell by 22.1% to -$3.4 million in 2025.
  • Business Quant data shows Cash from Financing Activities for OPRX at -$3.4 million in Q4 2025, -$258000.0 in Q3 2025, and -$4.5 million in Q2 2025.